Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4465-4473

  Hazen, Richard J ^a,b   Harvey, Robert J ^a   St Clair, Marty H ^a   Ferris, Robert G ^a   Freeman, George A ^a   Tidwell, Jeffrey H ^a   Schaller, Lee T ^a   Cowan, Jill R ^a   Short, Steven A ^b   Romines, Karen R ^a   Chan, Joseph H ^a,c   Boone, Lawrence R ^a  

^a Metabolic and Viral Diseases Center of Excellence for Drug Discovery   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Development and Medical Affairs Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GW 678248; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROGENY; VIRUS CULTURE; VIRUS ISOLATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NITRILES; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; SULFONAMIDES;

EID: 27644484382     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4465-4473.2005     Document Type: Article

References (28)

1. The AIDS Clinical Trials Group Virology Technical Advisory Committee and the Division of AIDS, National Institutes of Allergy and Infectious Diseases. 1994. HIV drug susceptibility assay. ACTG virology manual for HIV laboratories. RES 4-5. Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Md.
2. Andries, K., H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwels, and M. de Bethune. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
3. Bacheler, L. T., E. D. Anton, P. Kudish, D. Baker, J. Burnville, K. Krakowski, L. Bolling, M. Aujay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutation selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
4. Chan, J. H., G. A. Freeman, J. H. Tidwell, K. R. Romines, L. T. Schaller, J. R. Cowan, S. S. Gonzales, G. S. Lowell, C. W. Andrews, D. J. Reynolds, M. St. Clair, R. J. Hazen, R. G. Ferris, K. L. Creech, G. B. Roberts, S. A. Short, K. Weaver, G. W. Koszalka, and L. R. Boone. 2004. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 47:1175-1182.
5. Daluge, S. M., D. J. M. Purifoy, P. M. Savina, M. H. St. Clair, N. R. Parry, I. K. Dev, P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, J. A. Fyfe, M. R. Blum, D. R. Averett, R. E. Dornsife, B. A. Domin, R. Ferone, D. A. Lewis, and T. A. Krenitsky. 1994. 5-Chloro-2′,3′-dideoxy-3′- fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1590-1603.
6. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
7. D'Aquila, R. T., J. M. Schapiro, F. Brun-Vezinet, B. Clotet, B. Conway, L. M. Demeter, R. M. Grant, V. A. Johnson, D. R. Kuritzkes, C. Loveday, R. W. Shafer, and D. D. Richman. 2003. Drug resistance mutations in HIV-1. Top. HIV Med. 11:92-96.
8. Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. 1995. Mechanism of inhibition of reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:303-308.
9. 8a. Ferris, R. G., R. J. Hazen, G. B. Roberts, M. H. St. Clair, J. H. Chan, K. R. Romines, G. A. Freeman, J. H. Tidwell, L. T. Schaller, J. R. Cowan, S. A. Short, K. L. Weaver, D. W. Selleseth, K. R. Moniri, and L. R. Boone. 2005. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 49:4046-4051.
10. Fisher, A. G., E. Collalti, L. Ratner, R. C. Gallo, and F. Wong-Stall. 1985. A molecular clone of HTLV-III with biological activity. Nature 316:262-265.
11. Fumero, E., and D. Podzamczer. 2003. New patterns of HIV-1 resistance during HAART. Clin. Microbiol. Infect. 9:1077-1084.
12. Gerondelis, P., R. H. Archer, C. Palaniappan, R. C. Reichman, P. J. Fay, R. A. Bambara, and L. M. Demeter. 1999. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end and DNA 3′-end-directed RNase H activities. J. Virol. 73:5803-5813.
13. Hirsch, M. S., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, R. T. D'Aquila, L. M. Demeter, S. M. Hammer, V.A. Johnson, C. Loveday, J. W. Mellors, D. M. Jacobsen, and D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 37:1722-1723.
14. Huang, W., N. T. Parkin, Y. S. Lie, T. Wrin, R. Haubrich, S. Decks, N. Hellman, C. J. Petropoulos, and J. M. Whitcomb. 2000. A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication. Antivir. Ther. 5(Suppl. 3):24 (abstr. 30).
15. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 38:23-30.
16. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
17. King, R. W., R. M. Labe, C. D. Reid, and S. K. Erickson-Viitanen. 2002. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob. Agents Chemother. 46:1640-1646.
18. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
19. Mager, M. E. 1972. Data analysis in biochemistry and biophysics. Academic Press, Inc., New York, N.Y.
20. Miyoshi, I., I. Kubonishi, S. Yoshimoto, T. Akagi, Y. Ohtsuki, Y. Shiraishi, K. Nagata, and Y. Hinuma. 1981. Type C virus particles in a cord T-cell line derived by co-cultivating normal cord leukocytes and human leukaemic T cells. Nature 294:770-771.
21. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
22. Portsmouth, S., N. Imami, A. Pires, J. Stebbing, J. Hand, M. Nelson, F. Gotch, and B. G. Gazzard. 2004. Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated. HIV Med. 5:26-29.
23. Ren, J., L. E. Bird, P. P. Chamberlain, G. B. Stewart-Jones, D. I. Stuart, and D. K. Stammers. 2002. Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 99:14410-14415.
24. Schinazi, R., B. Larder, and J. Mellors. 2000. Mutations in retroviral genes associated with drug resistance. 2000-2001 update. Int. Antivir. News 8:65-91.
25. Schwartz, O., Y. Henin, V. Marechal, and L. Montagnier. 1988. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res. Hum. Retrovir. 4:441-448.
26. Selleseth, D. W., C. L. Talarico, T. Miller, M. W. Lutz, K. K. Biron, and R. J. Harvey. 2003. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 47:1468-1471.
27. Staszewski, S., J. Morales-Ramirez, K. T. Tashima, A. Rachlis, D. Skiest, J. Stanford, R. Stryker, P. Johnson, D. F. Labriola, D. Farina, D. J. Manion, and N. M. Ruiz. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. 341:1865-1873.
28. Witvrouw, M., C. Pannecouque, K. Van Laethem, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1999. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13:1477-1483.